HOYA Vision Care Announces New Sensity® 2 Light-Adaptive Lenses with Nearly Twice the Fadeback Speed

Advanced lens technology offers nearly twice the fadeback speed of its first generation Demand for light-adaptive lenses increases as two-thirds of patients now report sensitivity

Ophthalmic lens technology leader HOYA Vision Care announced today the next generation of its popular Sensity light-adaptive lenses. Two out of every three eyecare patients experience light sensitivity, making light-adaptive lenses a convenient and comfortable everyday vision solution for most patients.

A significant improvement compared to the previous generation of Sensity lenses, Sensity 2 lenses offer nearly twice the fadeback speed – approximately 42 percent faster.

Building on more than five years of success with its first-generation Sensity® lenses, HOYA Vision Care has created a product that rapidly darkens to a category 3 sun lens tint, fades back nearly twice as fast to a clear lens indoors, and still offers the same comfort, convenience, and protection as the entire Sensity family – with 100% UV protection, reduced glare from the sun when activated, and blue light protection indoors and outdoors2.

Available today, Sensity 2 lenses come in three intense natural color options: Silver Grey, Bronze Brown, and Emerald Green. They are compatible with HOYA’s Single Vision, Backside Progressives, and iD designs, as well as all of HOYA’s current antireflective treatments.

Two key technological innovations underlie the improved performance of the lenses: Stabilight Technology provides consistent performance and UV protection no matter the climate, cold or warm. Precision Technology ensures a microscopically accurate spin-coating process, creating superior adhesion for great scratch resistance.

“We are excited to bring Sensity 2 lenses to the market, offering an even faster fadeback that ECPs and their patients will greatly benefit from,” said Nick LaManna, Director of Product Management for HOYA Vision Care, North America. “Our continuous focus on improving our products has made us an industry leader in light-adaptive lens technology, and these are no exception.”

Interested ECPs can ask their HOYA Territory Sales Manager for more information about Sensity 2 light-adaptive lenses. Additionally, Visionary Alliance members are eligible to earn points when they choose Sensity 2 for their patients’ vision needs.


1. Harris Interactive Consumer Market Research Study, Global Report, Nov 2019: Usage Behavior When Outdoors

2. Based on internal testing of average light transmission between 381nm-500nm compared to standard clear lens

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.